ERBB2 and gastric cancer: The current global standard of the first‐line treatment of AGC consists of fluoropyrimidine plus platinum compound combined with immune checkpoint inhibitor if the patient has human epidermal growth factor receptor 2 (HER‐2)‐negative GC or with trastuzumab if HER‐2‐positive GC.3, 4